Acarbose/orlistat - Empros Pharma

Drug Profile

Acarbose/orlistat - Empros Pharma

Alternative Names: EMP-16-01

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Empros Pharma
  • Class Anorectics; Antihyperlipidaemics; Carbohydrates; Lactones; Obesity therapies
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity

Most Recent Events

  • 19 Dec 2016 Empros Pharma completes a phase II trial in Obesity in Sweden (EudraCT2016-001055-50)
  • 08 Aug 2016 Phase-II clinical trials in Obesity in Sweden (PO) (EudraCT2016-001055-50)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top